Blue Zones Project Citywide Kick-Off Event in Banning
BANNING, Calif., June 4, 2025 /PRNewswire/ -- Blue Zones Project invites the community to their free Kickoff this Saturday, June 7th at the Banning Repplier Park Aquatic Center from 10 a.m. - 1 p.m. This free celebration marks the public launch of Blue Zones Project in Banning, the exciting initiative working to transform the city into a place where healthy choices are easy.
Guest Speakers:Nick Buettner, Producer of the original Blue Zones expeditions to Okinawa, Japan; Costa Rica; and Ikaria, GreeceReuben Gonzales, Executive Director of Blue Zones Project Banning and Former Banning City CouncilmemberDr. Raul Ruiz, U.S. Representative for California's 25th Congressional DistrictYxstian Gutierrez, Riverside County Supervisor for the Fifth District
Free fun for all ages:Have FUN with live music, entertainment, games, and giveawaysEXPLORE the Blue Zones Power 9 throughout the eventLEARN about local resources, services, and programs available in your communityENJOY free tasty and healthy bites throughout the eventCONNECT through art, music, and other free family-friendly activities
RSVP and learn more: https://www.eventbrite.com/e/blue-zones-project-banning-kickoff-event-tickets-1316849455169
Blue Zones Project is a community-led initiative designed to help people live better, longer lives with lower rates of chronic disease by implementing permanent and semi-permanent changes to policies, systems, streets, surroundings, and social networks so it's easier for residents to eat wisely, move naturally, and connect more with others as they move throughout their day.
Blue Zones Project Banning is led by Executive Director Reuben Gonzales, who will lead the rollout and implementation of the Project in the region. Gonzales is a Banning native, community leader, and entrepreneur. He previously served as the Executive Director of the Banning Chamber of Commerce from 2021 to 2024, where he led business development initiatives and community engagement. He was also a Banning City Councilmember in 2022 and 2023, contributing to local governance and policymaking. Learn more about Gonzales and his full-time team: bluezonesprojectbanning.com/meet-our-team.
To learn more about Blue Zones Project Banning visit bluezonesprojectbanning.com.
About Blue Zones in Riverside CountyBlue Zones Project® is brought to Riverside County by Blue Zones and leading organizations Riverside University Health System - Public Health, Inland Empire Health Plan Foundation, Kaiser Permanente, Molina Healthcare, and Eisenhower Health. In collaboration with the County of Riverside and the Cities of Riverside, Banning, Palm Springs, and Coachella, this innovative partnership brings together private and public organizations under a shared vision to support, build, and measurably improve community well-being across the County. Blue Zones Projects have launched in Riverside, Banning, Coachella, and Palm Springs, while Mead Valley begins a policy-focused Blue Zones Activate. Over five years, local leadership and the local Blue Zones Project teams will implement the Blue Zones Life Radius® model to make healthy choices easier throughout the region through permanent and semi-permanent changes to the built environment, food environment, public policies, and social networks.
About Blue Zones ProjectBlue Zones Project is a community-led well-being improvement initiative designed to make healthy choices easier through permanent changes to a city's environment, policy, and social networks. Blue Zones Project is based on research by Dan Buettner, a National Geographic Fellow and New York Times best-selling author who identified five cultures of the world—or blue zones —with the highest concentration of people living to 100 years or older. Blue Zones Project incorporates Buettner's findings and works with cities to implement policies and programs that will move a community toward optimal health and well-being. Blue Zones launched the first pilot community in 2009 in Albert Lea, MN with groundbreaking results. Directly and also in partnership with Sharecare, the model has since been applied to more than 80 communities in the United States. Participating communities have experienced double-digit drops in obesity and tobacco use and have saved millions of dollars in healthcare costs. For more information, visit bluezones.com.
CONTACTS:Ashley Radkeashley@bluezones.com909-289-2578
Naomi Imatome-Yunnaomi@bluezones.com917-952-8534
View original content to download multimedia:https://www.prnewswire.com/news-releases/blue-zones-project-citywide-kick-off-event-in-banning-302473620.html
SOURCE Blue Zones
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Cumberland CID, One Cumberland, and the Chattahoochee River National Recreation Area Celebrate the Opening of Paces Mill After $6.3 Million Renewal
Newly restored park delivers safer access, greener infrastructure, and an expansive "front porch" on the Chattahoochee River for 270,000+ annual visitors Media Assets CUMBERLAND, Ga., June 7, 2025 /PRNewswire/ -- Hundreds of residents, elected officials, business and civic leaders, and park enthusiasts gathered this morning as the Cumberland Community Improvement District (CID), nonprofit One Cumberland, and the Chattahoochee River National Recreation Area (CRNRA) cut the ribbon on the renewed Paces Mill in the Palisades Unit of the CRNRA. The celebration marked the completion of Phase One of New Day Palisades, a two‑phase, $15.8 million project to rehabilitate 22 acres of greenspace and riverfront trails along the Chattahoochee River. "When we launched the New Day Palisades project, we envisioned more than just fresh pavement – we imagined a front porch on the Chattahoochee in the national park that belongs to everyone," said Bob Voyles, board chair of the Cumberland CID. "Today, that vision springs to life. The redesigned circulation system, resilient native landscapes, and direct river touchpoints mean every school bus, wheelchair, kayak trailer, and pair of hiking boots can arrive safely, move easily, and experience the river up close. This milestone reflects years of collaboration among the Cumberland CID, the National Park Service, our federal delegation, commercial property owners, and thousands of residents who asked us to re‑imagine their backyard national park." Phase One Highlights A newly engineered parking hub and bus‑drop loop untangle traffic and separate pedestrians from vehicles, creating a welcoming destination for more than 270,000 annual visitors. Space for a sweeping native meadow, bioswales and precision grading now capture and filter stormwater before it reaches the river, stabilizing soils and enhancing ecological resilience across the 22‑acre site. Rebuilt boardwalks, gently graded paths guide every visitor – regardless of ability – directly to the water's edge within minutes, turning the Chattahoochee into an immersive classroom and playground. The $6.3 million phase one was funded with $4.3 million provided by the Cumberland CID and $2 million in federal appropriations championed by Georgia's congressional delegation, including U.S. Senators Jon Ossoff and Raphael Warnock, and U.S. Representatives Barry Loudermilk, Lucy McBath, and David Scott. "Today's ribbon cutting is a celebration of partnerships and a representation of what is possible when federal, state, and local leaders work together in service to our community," said U.S. Representative Lucy McBath (GA-06). "The reopening of Paces Mill shows how smart investments in public land improve our health, strengthen our economy, and preserve Georgia's natural treasures for generations to come. As your Congresswoman, I was proud to help secure federal funding for Phase One of this project, and I look forward to remaining engaged as we look ahead to the next stage of development for this wonderful community asset." "The completion of Phase One marks an exciting time in the effort to revitalize Paces Mill, so the hundreds of thousands of visitors each year can continue to enjoy this area for decades to come," said Congressman Barry Loudermilk (GA-11). "I'm especially proud of the hard work Cumberland Community Improvement District and the nonprofit One Cumberland have done to make this vision a reality, and for the funds Congress was able to appropriate to help complete Phase One." "The New Day Palisades project is more than a transformation – it's a strategic investment in Cumberland's ecological assets," said Rob Garcia, board chair of One Cumberland. "Through careful planning, we are ensuring Paces Mill remains a cherished destination for outdoor recreation while strengthening our community's identity with improved accessibility, cultural enrichment, and environmental stewardship. We look forward to engaging the community to help move forward the vision of Phase Two." As funding allows, the $9.5 million Phase Two will begin in 2026 with an expected completion in spring 2027. One Cumberland will work to help raise funds for Phase Two. Phase Two will feature a new Visitor Information Center with enhanced restrooms and changing facilities, an open-air pavilion, and additional elements that will provide greater access to the Chattahoochee River. Looking ahead: Phase Two (2026‑2027)Planning is already underway for a $9.5 million second phase that will crown Paces Mill with: A fully ADA‑accessible Visitor Information Center featuring modern restrooms and changing rooms. An open‑air pavilion for environmental education and community events. Broad river steps beneath the U.S. 41 bridge and additional habitat and trail enhancements. River overlooks to increase accessibility to the Chattahoochee River. When complete in spring of 2027 – timed to coincide with the CRNRA's 50th anniversary, established in 1978 when President Jimmy Carter signed the enabling legislation – the two‑phase effort will stand as the single largest investment in public access to the Chattahoochee within the national park. To learn more about the New Day Palisades project, please visit About Cumberland CIDThe Cumberland Community Improvement District (CID), Georgia's first CID, is one of the nation's premier models of public-private collaboration. More than 190 Commercial property owners pay additional property taxes, and the CID leverages these funds to advance key projects for increased access, better connectivity, and a more vibrant character throughout the Cumberland area. Each year, the CID creates more value for the community by initiating and leading enhancements to make Cumberland a more attractive place to operate a business, to work, and to live. Today, Cumberland has a $26.6 billion annual impact on Georgia's economy. Cumberland is home to leading companies including The Home Depot, Papa Johns, TKE, Comcast, Genuine Parts Company, and more. To learn more about the Cumberland CID, the Cumberland Sweep, and the Cumberland Hopper autonomous shuttle pilot program, please visit About One CumberlandOne Cumberland is committed to ensuring Cumberland's national parkland receives sustainable investment, care, and recognition. Established in 2022 by the Cumberland CID, the nonprofit aims to create a greater sense of ownership, affiliation, and connectivity between Cumberland and the community. One Cumberland's mission is to protect and conserve the natural resources of Cumberland and establish the district as a vibrant, diverse community through the enrichment of cultural amenities, quality of life, improved access, and environmental stewardship. For more information visit View original content to download multimedia: SOURCE Cumberland Community Improvement District Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus
Yahoo
17 hours ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme（the tradename of Merck & Co., Inc., Rahway, NJ, USA）is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy； OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy； OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech（ a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
